Robert B. Bazemore's most recent trade in Ardelyx Inc was a trade of 39,715 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ardelyx Inc | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 39,715 | 39,715 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 26,455 | 68,006 (0%) | 0% | 0 | Common Stock | |
| Nuvation Bio Inc (Class A) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 123,397 | 123,397 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 123,731 | 123,731 | - | - | Warrants to purchase American Depositary Shares ("ADRs") | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 123,731 | 123,731 | - | - | Pre-Funded Warrants to purchase ADRs | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 30,932 | 30,932 | - | - | Warrants to purchase ADRs | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 16 Dec 2025 | 30,932 | 30,932 | - | - | Pre-Funded Warrants to purchase ADRs | |
| Ardelyx Inc | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 54,059 | 54,059 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 41,551 | 41,551 (0%) | 0% | 0 | Common Stock | |
| Nuvation Bio Inc (Class A) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 292,983 | 292,983 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 44,642 | 44,642 | - | - | Series A Warrants (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 44,642 | 44,642 | - | - | Series B Warrants (Right to Buy) | |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 1.12 per share. | 06 Mar 2025 | 44,642 | 44,642 (0%) | 0% | 1.1 | 49,999 | American Depositary Shares representing Ordinary Shares |
| Akari Therapeutics PLC (ADR) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 5,000,000 | 5,000,000 | - | - | Stock Option (Right to Buy) | |
| Nuvation Bio Inc (Class A) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 200,801 | 200,801 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 40,243 | 40,243 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 49,237 | 49,237 | - | - | Stock Option (Right to Buy) | |
| Nuvation Bio Inc (Class A) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 366,744 | 366,744 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Nuvation Bio Inc (Class A) | Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 140,713 | 140,713 | - | - | Stock Option (Right to Buy) |